Michelle Divelbiss is an associate in the Intellectual Property and Food and Drug Administration (“FDA”) practice groups. Her practice involves patent litigation, particularly cases brought under the Hatch-Waxman Act, and counseling relating to FDA matters.
Michelle was Online Editor of The George Washington Law Review. Prior to earning her JD, she was a research associate at a biotechnology company focused on the development and commercialization of prognostic tests relating to cancer metastasis. She was a Summer Associate with Axinn in 2018.
- American Bar Association
- American Intellectual Property Law Association
- Axinn FDA Update: A Difficult Analysis Is Not Necessarily a Deferential Analysis, Axinn Update, September 21, 2020
- FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors, Cell & Gene, August 6, 2020
- FDA Informal Guidance Process, Lexis Practice Advisor, July 30, 2020
- Chevron’s Hard-Hitting Footnote Nine Revived by Kisor v. Wilkie and Recent Decisions on Deference, FDLI, February 21, 2020
- Fed. Circ. May Limit USPTO’s Standing to Intervene, Law360, February 12, 2020
- Open the Floodgates: The Potential Impact on Litigation Against FDA if the Supreme Court Reverses or Curtails Chevron Deference, FDLI, December 18, 2019
- Can the FDA Salvage Interchangeable Follow-On Biologics?, BioProcess Online / Biosimilar Development, November 19, 2019
- Discretionary Denials at Patent Court Thwart Generic Drugmakers, Bloomberg Law, November 1, 2019
- JD, with honors – The George Washington University Law School (2019)
- MS, Medical Science – Boston University (2016)
- BA, Spanish Studies – Santa Clara University (2011)
- District of Columbia